enveloped

By Targets:	Antibiotic (1) Bacterial (1) Fungal (1) HCV (1) HIV (1) HPV (1) HSV (3) Influenza Virus (3) Isotope-Labeled Compounds (1) Parasite (1) Proton Pump (1) SARS-CoV (7)
By Research Areas:	Infection (12) Inflammation/Immunology (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14904A

Umifenovir hydrochloride Maximum Cited Publications 8 Publications Verification	Influenza Virus SARS-CoV	Infection
Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an anti-influenza virus agent. Umifenovir hydrochloride could effectively inhibit the fusion of virus with host cells . Umifenovir hydrochloride is an efficient inhibitor of SARS-CoV-2 in vitro. Anti-inflammatory activity .

HY-14904

Umifenovir Maximum Cited Publications 8 Publications Verification	SARS-CoV Influenza Virus	Infection
Umifenovir is a potent, orally active broad-spectrum antiviral agent with activity against a number of enveloped and non-enveloped viruses. Umifenovir is used as an anti-influenza virus agent. Umifenovir could effectively inhibit the fusion of virus with host cells . Umifenovir is an efficient inhibitor of SARS-CoV-2 in vitro . Umifenovir shows anti-inflammatory activity .

HY-151267

SARS-CoV-2-IN-25	SARS-CoV	Infection
SARS-CoV-2-IN-25 (Compound CP026) is a potent SARS-CoV-2 spike pseudoparticle transduction inhibitor with an IC₅₀ of 1.6 μM. SARS-CoV-2-IN-25 inhibits enveloped viruses and liposomes .

HY-151267A

SARS-CoV-2-IN-25 disodium	SARS-CoV	Infection
SARS-CoV-2-IN-25 (Compound CP026) disodium is a potent SARS-CoV-2 spike pseudoparticle transduction inhibitor with an IC₅₀ of 1.6 μM. SARS-CoV-2-IN-25 disodium inhibits enveloped viruses and liposomes .

HY-14904AS

Umifenovir-d6 hydrochloride	Isotope-Labeled Compounds Influenza Virus SARS-CoV	Infection
Umifenovir-d₆ (hydrochloride) is the deuterium labeled Umifenovir hydrochloride. Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an anti-influenza virus agent. Umifenovir hydrochloride could effectively inhibit the fusion of virus with host cells[1][2]. Umifenovir hydrochloride is an efficient inhibitor of SARS-CoV-2 in vitro. Anti-inflammatory activity[3].

HY-B0222

1-Docosanol 1 Publications Verification Behenyl alcohol	HSV	Infection
1-Docosanol (Behenyl alcohol) is a saturated fatty alcohol with reported inhibitory activity against lipid-enveloped viruses, including herpes simplex virus (HSV) .

HY-19874

RFI-641
RFI-641 is a selective inhibitor of the respiratory syncytial virus (RSV), with an IC₅₀ of 50 nM. RFI-641 inhibit binding and fusion of enveloped virus via interaction with the viral fusion protein .

HY-156979

RBT-9	SARS-CoV HCV	Infection
RBT-9 prevents progression to severe COVID-19 and organ failure. RBT-9 also has antiviral effects, as demonstrated in several enveloped viruses, including influenza, HCV, dengue, and yellow fever .

HY-B0222S

1-Docosanol-d45	HSV	Infection
1-Docosanol-d₄₅ is the deuterium labeled 1-Docosanol. 1-Docosanol is a saturated fatty alcohol used traditionally as an emollient, emulsifier, and thickener in cosmetics, and nutritional supplement. 1-Docosanol is an inhibitor of lipid-enveloped viruses including herpes simplex.

HY-132191

Pradimicin A	Fungal SARS-CoV HIV	Infection
Pradimicin A (PRM-A) is a potent antifungal agent, with an MIC of 4 μg/mL against Candida rugosa. Pradimicin A has antiviral activities against CoV, HIV and other enveloped viruses. Pradimicin A shows aggregation property, and can recognize d-Man in the presence of Ca ²⁺ ion .

HY-129555

Surfactin 5 Publications Verification	Bacterial HSV Antibiotic	Infection
Surfactin is a potent cyclic lipopeptide biosurfactants consists of four isomers (Surfactin A, B, C and D), which mediates flux of mono-and divalent cations, such as calcium, across lipid bilayer membranes. Surfactin can act as an antimicrobial adjuvant with anti-bacterial, anti-fungal, antimycoplasma and hemolytic effects . Surfactin also has antiviral activity against a variety of enveloped viruses .

HY-17421

Tenatoprazole TU-199	Proton Pump	Infection Inflammation/Immunology
Tenatoprazole (TU-199) is an orally active imidazopyridine-based proton pump inhibitor with a prolonged plasma half-life. Tenatoprazole inhibits hog gastric H ⁺/K ⁺-ATPase activity with an IC₅₀ of 6.2 μM. Tenatoprazole blocks the interaction of ubiquitin with the ESCRT-1 factor Tsg101, inhibits production of several enveloped viruses, including EBV .

HY-P5694

Human α-defensin 5	HPV Parasite	Infection
Human α-defensin 5 is an antiviral peptide. Human α-defensin 5 blocks infection of non-enveloped viruses, including AdV, HPV, and polyomaviruses (IC₅₀: 0.6-1.25 μM for HPV16). Human α-defensin 5 can bind to the viral capsid and blocks escape of the virus from the endosome. Human α-defensin 5 increases HIV binding to the cell surface. Human α-defensin 5 also has parasiticidal activity .

Cat. No.	Product Name

HY-L073

Anti-Hepatitis C Virus Compound Library	283 compounds
Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle. MCE offers a unique collection of 283 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Anti-Hepatitis C Virus Compound Library

283 compounds

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 283 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Cat. No.	Product Name	Target	Research Area

HY-P5694

Human α-defensin 5	HPV Parasite	Infection
Human α-defensin 5 is an antiviral peptide. Human α-defensin 5 blocks infection of non-enveloped viruses, including AdV, HPV, and polyomaviruses (IC₅₀: 0.6-1.25 μM for HPV16). Human α-defensin 5 can bind to the viral capsid and blocks escape of the virus from the endosome. Human α-defensin 5 increases HIV binding to the cell surface. Human α-defensin 5 also has parasiticidal activity .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0222

1-Docosanol 1 Publications Verification Behenyl alcohol	Infection Structural Classification Natural Products other families Classification of Application Fields Source classification Plants Disease Research Fields	HSV
1-Docosanol (Behenyl alcohol) is a saturated fatty alcohol with reported inhibitory activity against lipid-enveloped viruses, including herpes simplex virus (HSV) .

HY-129555

Surfactin 5 Publications Verification	Infection Structural Classification Natural Products Microorganisms Classification of Application Fields Source classification Disease Research Fields	Bacterial HSV Antibiotic
Surfactin is a potent cyclic lipopeptide biosurfactants consists of four isomers (Surfactin A, B, C and D), which mediates flux of mono-and divalent cations, such as calcium, across lipid bilayer membranes. Surfactin can act as an antimicrobial adjuvant with anti-bacterial, anti-fungal, antimycoplasma and hemolytic effects . Surfactin also has antiviral activity against a variety of enveloped viruses .

Cat. No.	Product Name	Chemical Structure

HY-14904AS

Umifenovir-d6 hydrochloride
Umifenovir-d₆ (hydrochloride) is the deuterium labeled Umifenovir hydrochloride. Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an anti-influenza virus agent. Umifenovir hydrochloride could effectively inhibit the fusion of virus with host cells[1][2]. Umifenovir hydrochloride is an efficient inhibitor of SARS-CoV-2 in vitro. Anti-inflammatory activity[3].

Umifenovir-d6 hydrochloride

Umifenovir-d₆ (hydrochloride) is the deuterium labeled Umifenovir hydrochloride. Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an anti-influenza virus agent. Umifenovir hydrochloride could effectively inhibit the fusion of virus with host cells[1][2]. Umifenovir hydrochloride is an efficient inhibitor of SARS-CoV-2 in vitro. Anti-inflammatory activity[3].

HY-B0222S

1-Docosanol-d45
1-Docosanol-d₄₅ is the deuterium labeled 1-Docosanol. 1-Docosanol is a saturated fatty alcohol used traditionally as an emollient, emulsifier, and thickener in cosmetics, and nutritional supplement. 1-Docosanol is an inhibitor of lipid-enveloped viruses including herpes simplex.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds